Targeting KRAS mutations and immune suppression in pancreatic cancer
Official title: Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
Funded at University of California Los Angeles · NIH-11035133 · Data updated 2026-11-12
This study is looking at how a new treatment for pancreatic cancer that targets a specific mutation can help your immune system fight the tumors better, and it aims to find the best way to combine this treatment with other therapies to improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | March 1, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $585,317 |
| NIH project number | 5R01CA260678-05 |
| Project ID | NIH-11035133 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with KRAS mutations.
✕Less likely to help
Patients with pancreatic cancer who do not have KRAS mutations or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates how targeting KRAS mutations in pancreatic cancer can enhance the immune response against tumors. It employs advanced techniques such as transcriptomic, proteomic, and metabolomic analyses in both human and animal models to understand the effects of KRASG12C inhibitors. The goal is to identify how these inhibitors can be combined with immune checkpoint blockade therapies to improve treatment outcomes for patients with pancreatic ductal adenocarcinoma. By understanding the metabolic changes and immune responses triggered by these treatments, the research aims to develop more effective therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer by enhancing their immune response against tumors.
How similar studies have gone: Other research has shown promising results with similar approaches targeting KRAS mutations and immune modulation, indicating potential for success in this area.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Radu, Caius Gabriel — University of California Los Angeles
- Study coordinator: Radu, Caius Gabriel
Related research
Other NIH-funded projects on the same topics.
-
Fibroblast-made GABA fuels PDAC immune suppression
In people with pancreatic cancer, this study explores how a specific cell type in the tumor environment uses a brain-like chemical (GABA) to dampen immune attack against the cancer.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.